Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-9137255b",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "claude-sonnet-4",
  "action": "propose",
  "content": "# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration\n\n## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor\n**Description:** DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.\n\n**Target:** DNAJB6 (DnaJ heat shock protein family member B6)\n\n**Supporting Evidence:** DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations (PMID: 23064266). HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins (PMID: 31358969). DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases (PMID: 28887542).\n\n**Predicted Outcomes:** DNAJB6 overexpression should reduce cross-seeding between different proteinopathies in cellular and animal models. Small molecule DNAJB6 activators should show therapeutic efficacy in mixed pathology models.\n\n**Confidence:** 0.75\n\n## Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance Pathway\n**Description:** TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.\n\n**Target:** TREM2 (Triggering receptor expressed on myeloid cells 2)\n\n**Supporting Evidence:** TREM2 variants significantly modify risk across multiple neurodegenerative diseases (PMID: 31398344). Engineered TREM2 constructs can be designed to recognize specific protein conformations (PMID: 29899446). TREM2 activation promotes microglial phagocytosis of protein aggregates (PMID: 32719508).\n\n**Predicted Outcomes:** Engineered TREM2 constructs should show enhanced clearance of cross-seeded aggregates in mixed pathology models. Treatment should reduce propagation of heterologous seeding between brain regions.\n\n**Confidence:** 0.65\n\n## Hypothesis 3: Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption\n**Description:** Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.\n\n**Target:** PHB2 (Prohibitin 2)\n\n**Supporting Evidence:** Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria (PMID: 27559042). TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption (PMID: 31591533). Prohibitin-2 modulates protein aggregation through conformational changes (PMID: 28890334).\n\n**Predicted Outcomes:** PHB2 modulation should reduce cross-seeding specifically at mitochondrial sites. Treatment should preserve mitochondrial function while reducing heterologous protein interactions.\n\n**Confidence:** 0.70\n\n## Hypothesis 4: RNA-Binding Competition Therapy for TDP-43 Cross-Seeding\n**Description:** Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.\n\n**Target:** TARDBP (TDP-43) RNA-binding domains\n\n**Supporting Evidence:** TDP-43 binds tau mRNA and regulates its translation (PMID: 31570834). RNA molecules can template protein aggregation and cross-seeding (PMID: 29262350). Synthetic aptamers successfully modulate TDP-43 RNA interactions (PMID: 30482948).\n\n**Predicted Outcomes:** RNA aptamer treatment should specifically reduce TDP-43-mediated cross-seeding with tau and α-synuclein. Effect should be reversible and show selectivity for pathological interactions.\n\n**Confidence:** 0.60\n\n## Hypothesis 5: Transglutaminase-2 Cross-Linking Inhibition Strategy\n**Description:** Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.\n\n**Target:** TGM2 (Transglutaminase 2)\n\n**Supporting Evidence:** Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions (PMID: 25242045). TG2 activity is elevated in multiple neurodegenerative diseases (PMID: 27784544). Selective TG2 inhibitors reduce protein aggregation (PMID: 31756126).\n\n**Predicted Outcomes:** Selective TG2 inhibition should reduce stability of cross-seeded aggregates. Treatment should show efficacy in mixed pathology models without affecting normal cellular TG2 functions.\n\n**Confidence:** 0.72\n\n## Hypothesis 6: Liquid-Liquid Phase Separation Modifier Therapy\n**Description:** Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.\n\n**Target:** Stress granule and P-body formation (G3BP1, PABP1)\n\n**Supporting Evidence:** TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs (PMID: 31959759). Liquid-liquid phase separation drives pathological protein aggregation (PMID: 32296183). Small molecules can modulate biomolecular condensate properties (PMID: 33658718).\n\n**Predicted Outcomes:** Phase separation modulators should reduce co-localization and cross-seeding in stress granules. Treatment should show broad efficacy across multiple proteinopathies.\n\n**Confidence:** 0.68\n\n## Hypothesis 7: Glycosaminoglycan Template Disruption Approach\n**Description:** Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.\n\n**Target:** Heparan sulfate proteoglycans (HSPG2, syndecans)\n\n**Supporting Evidence:** Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43 (PMID: 29728651). Heparan sulfate facilitates cross-seeding between different amyloid proteins (PMID: 26755048). GAG-targeting therapeutics show promise in proteinopathies (PMID: 31969712).\n\n**Predicted Outcomes:** GAG disruption should reduce cross-seeding efficiency in vitro and in vivo. Treatment should show selectivity for pathological vs. physiological protein-GAG interactions.\n\n**Confidence:** 0.73",
  "tokens_used": "1772"
}